Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Itraconazole

FDA-approved product (capsule, oral), marketed as Itraconazole, Onmel, Sporanox and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Itraconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aspergillosis
  • Blastomycosis
  • Candidiasis
  • Fungal infectious disease
  • Lung disease
  • Tinea
  • Tinea unguium

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC02; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae34.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Itraconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Itraconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Role of Adjuvant Corneal Crosslinking in the Management of Infective Keratitis

    NCT06967376 · start 2018-05-21

    Registered record
    Registry ID
    NCT06967376
    Conditions
    Infective Keratitis
    Interventions
    Corneal Collagen Cross-Linking Solutions; Topical Antimicrobial/Antifungal Medications
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2018-05-21
    Completion
    2022-02-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfective Keratitis
    InterventionCorneal Collagen Cross-Linking Solutions; Topical Antimicrobial/Antifungal Medications
    PhaseEarly phase 1
    Registry statusCompleted

  • This Study in Healthy Men Tests How Itraconazole Influences the Amount of BI 1015550 in the Blood

    NCT03403439 · start 2018-05-03

    Registered record
    Registry ID
    NCT03403439
    Conditions
    Healthy
    Interventions
    BI 1015550; itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-05-03
    Completion
    2018-07-20
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBI 1015550; itraconazole
    PhasePhase 1
    Registry statusCompleted

  • A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy Volunteers

    NCT03499106 · start 2018-04-12

    Registered record
    Registry ID
    NCT03499106
    Conditions
    Healthy
    Interventions
    IW-1973; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-04-12
    Completion
    2018-07-06
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionIW-1973; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • Antifungal Drugs in Treatment of Onychomycosis

    NCT03171584 · start 2017-07-01

    Registered record
    Registry ID
    NCT03171584
    Conditions
    Antifungal Drugs in Onychomycosis
    Interventions
    Terbinafine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-07-01
    Completion
    2019-11-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntifungal Drugs in Onychomycosis
    InterventionTerbinafine
    PhasePhase 3
    Registry statusUnknown

  • Proof-of-Concept Superiority Trial of Fosravuconazole Versus Itraconazole for Eumycetoma in Sudan

    NCT03086226 · start 2017-05-09

    Registered record
    Registry ID
    NCT03086226
    Conditions
    Mycetoma
    Interventions
    Fosravuconazole; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-05-09
    Completion
    2022-03-07
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycetoma
    InterventionFosravuconazole; Itraconazole
    PhasePhase 2
    Registry statusCompleted

  • A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy

    NCT02895529 · start 2016-11-30

    Registered record
    Registry ID
    NCT02895529
    Conditions
    Hematologic Neoplasms
    Interventions
    Itraconazole; Caspofungin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2016-11-30
    Completion
    2018-05-02
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematologic Neoplasms
    InterventionItraconazole; Caspofungin
    PhasePhase 4
    Registry statusTerminated

  • A Study To Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy Volunteers

    NCT02838264 · start 2016-08-16

    Registered record
    Registry ID
    NCT02838264
    Conditions
    Healthy
    Interventions
    PF-06463922; PF-06463922; PF-06463922; PF-06463922; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-08-16
    Completion
    2017-05-03
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPF-06463922; PF-06463922; PF-06463922; PF-06463922 +1 more
    PhasePhase 1
    Registry statusCompleted

  • Topical Itraconazole in Treating Patients With Basal Cell Cancer

    NCT02735356 · start 2016-05-05

    Registered record
    Registry ID
    NCT02735356
    Conditions
    Skin Basal Cell Carcinoma
    Interventions
    Itraconazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2016-05-05
    Completion
    2017-10-10
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Basal Cell Carcinoma
    InterventionItraconazole; Placebo
    PhaseEarly phase 1
    Registry statusCompleted

  • A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults

    NCT02729467 · start 2016-03

    Registered record
    Registry ID
    NCT02729467
    Conditions
    Healthy
    Interventions
    JNJ-53718678; Itraconazole; Rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-03
    Completion
    2016-06
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionJNJ-53718678; Itraconazole; Rifampicin
    PhasePhase 1
    Registry statusCompleted

  • A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) Given by Mouth in Healthy Volunteers

    NCT02633709 · start 2016-01-07

    Registered record
    Registry ID
    NCT02633709
    Conditions
    Spinal Muscular Atrophy
    Interventions
    Itraconazole; Placebo; Risdiplam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-01-07
    Completion
    2016-08-04
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Muscular Atrophy
    InterventionItraconazole; Placebo; Risdiplam
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects

    NCT02341482 · start 2015-02-05

    Registered record
    Registry ID
    NCT02341482
    Conditions
    Healthy
    Interventions
    PF-04958242; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-02-05
    Completion
    2015-03-31
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionPF-04958242; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects

    NCT02045849 · start 2014-01-28

    Registered record
    Registry ID
    NCT02045849
    Conditions
    Infections, Bacterial
    Interventions
    GSK2140944 capsule; GSK2140944 tablet; Itraconazole capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-01-28
    Completion
    2014-08-21
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Bacterial
    InterventionGSK2140944 capsule; GSK2140944 tablet; Itraconazole capsule
    PhasePhase 1
    Registry statusCompleted

  • Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours

    NCT01772563 · start 2013-02-04

    Registered record
    Registry ID
    NCT01772563
    Conditions
    Neoplasms
    Interventions
    volasertib; itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-02-04
    Completion
    2021-04-22
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    Interventionvolasertib; itraconazole
    PhasePhase 1
    Registry statusCompleted

  • Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole

    NCT01913379 · start 2011-08

    Registered record
    Registry ID
    NCT01913379
    Conditions
    Healthy Subjects; Pharmacokinetics; Drug-Drug Interaction
    Interventions
    MDV3100; Gemfibrozil; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-08
    Completion
    2011-12
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects; Pharmacokinetics; Drug-Drug Interaction
    InterventionMDV3100; Gemfibrozil; Itraconazole
    PhasePhase 1
    Registry statusCompleted

  • Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis

    NCT01321827 · start 2011-04

    Registered record
    Registry ID
    NCT01321827
    Conditions
    Allergic Bronchopulmonary Aspergillosis
    Interventions
    Glucocorticoids; Itraconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2011-04
    Completion
    2015-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergic Bronchopulmonary Aspergillosis
    InterventionGlucocorticoids; Itraconazole
    PhasePhase 2 / Phase 3
    Registry statusCompleted